CASRAI Dictionary

Tag: research misconduct nhs

  • GMC Research Misconduct: Process Explained

    When the General Medical Council (GMC) investigates a doctor for research misconduct, it runs a fitness-to-practise process, not a scientific-integrity audit — assessing whether conduct such as data fabrication, falsification, plagiarism, undisclosed conflicts, or dishonesty means the doctor’s registration should be restricted, suspended, or removed. That process is legally and procedurally distinct from the research-governance route run through NHS trusts and the Health Research Authority.

    GMC research misconduct describes conduct by a UK-registered doctor — fabricating or falsifying research data, plagiarism, or a serious breach of the GMC’s Good practice in research standards — that the GMC investigates through its statutory fitness-to-practise procedure to decide whether registration should be restricted. This article maps that regulatory pathway, distinct from the NHS governance process covered elsewhere on this site.

    What counts as research misconduct under GMC guidance?

    The GMC’s Good practice in research guidance — supplementary to Good medical practice — sets the standards doctors must meet when designing, organising, or carrying out research in the UK. It requires doctors to conduct research “honestly and with integrity” and to “report evidence of financial or scientific fraud, or other failures to follow the requirements of the UK Policy Framework, to an appropriate person in your employing or contracting organisation and relevant regulatory bodies.”

    In practice, conduct that can trigger a GMC concern includes:

    • Fabricating or falsifying research data or results
    • Plagiarism, or misattributing authorship and contribution
    • Failing to obtain or properly document informed consent from participants
    • Undeclared financial or commercial conflicts of interest
    • Proceeding without required research ethics committee or Health Research Authority approval
    • Dishonesty in reporting, publishing, or communicating research findings

    Not every departure from the guidance is treated as serious. The GMC’s threshold is whether the conduct raises a genuine question about the doctor’s fitness to practise — a public-protection test, not a general research-quality assessment.

    How does a GMC investigation into research misconduct work?

    A GMC fitness-to-practise investigation follows a defined sequence, whether the concern is clinical or research-related.

    1. Triage and provisional enquiry. The GMC receives a complaint — from a patient, colleague, employer, journal, whistleblower, or another regulator — and screens it against its threshold criteria for fitness-to-practise concerns.
    2. Full investigation and Rule 7 letter. If the threshold is met, a case officer gathers evidence — research data, protocols, correspondence, expert reports — and the doctor is formally notified of the allegation and invited to respond in writing under Rule 7 of the General Medical Council (Fitness to Practise) Rules 2004.
    3. Case examiner decision. Since reforms took effect in October 2015, two case examiners — one medical, one lay — review the completed investigation. They can close the case, issue a warning, agree undertakings with the doctor, or refer the matter to a full hearing.
    4. Interim Orders Tribunal (IOT). Where there is an immediate risk to patients or public confidence, the GMC can refer a doctor to an Interim Orders Tribunal at any stage, which can suspend or restrict practice while the investigation continues.
    5. Medical Practitioners Tribunal Service (MPTS) hearing. Contested or serious cases proceed to a public hearing before the MPTS — the tribunal function that has operated as structurally separate from the GMC’s investigative arm since the Health and Social Care Act 2012 — which determines the facts and whether fitness to practise is impaired.

    Timescales vary considerably. Straightforward cases can close within months of the initial complaint; research-misconduct allegations involving data audits, statistical experts, and multiple witnesses commonly take a year or longer before a tribunal hearing is listed.

    How does GMC oversight differ from other UK research-integrity bodies?

    A common misunderstanding is that the GMC is the primary body for adjudicating research misconduct. It is not: the GMC’s jurisdiction is limited to whether an individual doctor’s registration should be affected. Separate bodies handle research governance, publication integrity, and institutional investigation — often before, or without, GMC involvement.

    Body Role Typical trigger Possible outcome
    GMC / MPTS Regulates individual doctors’ fitness to practise Allegation of dishonesty, fraud, or serious breach of Good practice in research Warning, conditions, suspension, erasure
    Health Research Authority (HRA) Approves and oversees research governance under the UK Policy Framework for Health and Social Care Research Non-compliance with ethics approval, consent, or protocol Withdrawal of approval; referral to sponsor or regulator
    Employing NHS trust or university First-line investigator under institutional research-governance policy Any internal concern or whistleblower report Internal disciplinary action; referral to GMC/HRA
    Committee on Publication Ethics (COPE) Advises journals on handling integrity concerns in published work Concern about a specific paper Correction, expression of concern, retraction
    UK Research Integrity Office (UKRIO) Independent advisory body on research integrity practice Institutions seeking independent panel members or advice Advisory report to the commissioning institution

    These routes run in parallel. A university may investigate authorship and data-integrity questions — closer to the authorship contribution disputes handled through institutional and publisher channels — while separately reporting a doctor to the GMC if dishonesty or patient safety is in issue. The GMC does not duplicate a university’s or journal’s fact-finding; it relies on it as evidence.

    What sanctions can follow a finding of research misconduct?

    If an MPTS tribunal finds a doctor’s fitness to practise impaired because of research misconduct, it must select from a defined range of sanctions, applying the principle that the overriding objective is public protection and public confidence in the profession — not punishment of the doctor.

    • No further action — exceptional, where impairment is minor and already remediated
    • Warning — a formal recorded statement that conduct fell below the expected standard
    • Undertakings — voluntary, monitored commitments agreed with the doctor
    • Conditions on registration — for example, mandatory supervision of any future research activity
    • Suspension — time-limited removal of the right to practise
    • Erasure — removal from the medical register, the most severe outcome

    Erasure is the outcome most associated with persistent or serious dishonesty. In May 2010, a GMC fitness-to-practise panel found Andrew Wakefield guilty of dishonesty and serious ethical failings in the research underlying his 1998 Lancet paper linking the MMR vaccine to autism; he was erased from the medical register, and The Lancet formally retracted the paper the same year. The case remains the most cited illustration of how a research-integrity failure can translate directly into a fitness-to-practise sanction.

    Answer-first Q&A on GMC research misconduct

    What is misconduct in GMC cases?

    Under GMC processes, misconduct is any act or omission that falls short of the standards set out in Good medical practice and, for researchers, Good practice in research. Not every shortfall is serious; the GMC investigates only conduct grave enough to raise a genuine fitness-to-practise concern.

    What are the three types of research misconduct?

    Research-integrity frameworks generally group misconduct into three core categories: fabrication (inventing data), falsification (manipulating data or results), and plagiarism (using others’ work without attribution). GMC cases frequently add a further concern — undisclosed conflicts of interest — where dishonesty is also alleged.

    How long does a GMC investigation take?

    Length varies with complexity. Straightforward complaints can close within months, but research-misconduct investigations involving expert data review, multiple witnesses, and possible MPTS hearings commonly extend beyond a year before a tribunal date is set.

    What are the GMC’s core ethical domains?

    The GMC’s Good medical practice framework, which underpins every fitness-to-practise judgment, is organised around domains covering knowledge and professional development, patient partnership and communication, safety and quality, and trust and professionalism — the same domains applied when a research-conduct concern is assessed.

    What this means for institutions and individual researchers

    For research administrators, the practical implication is sequencing: internal research-governance and HRA-facing processes should establish the facts first, with a GMC referral triggered where dishonesty, patient safety, or public confidence is engaged — not as a substitute for institutional investigation. For doctor-researchers, Good practice in research compliance is not a separate track from clinical professionalism: a breach in the research context is assessed against the same fitness-to-practise standard as a clinical failing, and can carry the same range of sanctions, up to erasure.

    As UK research governance tightens around transparency and conflict-of-interest declarations, doctors involved in research should expect institutional reporting obligations to the GMC to be treated as a normal, not exceptional, part of research oversight.

  • Research Misconduct NHS: How Governance Differs from University Policy

    Research misconduct NHS allegations are not resolved as a purely internal university disciplinary matter. Because a designated research sponsor and the Health Research Authority (HRA) hold formal accountability under the UK Policy Framework for Health and Social Care Research, misconduct in NHS-hosted clinical studies routes through trust-level research governance and, for doctors, potential General Medical Council scrutiny — running alongside, not instead of, any university process.

    Research misconduct is behaviour that deliberately or recklessly falls short of the standards expected in the conduct of research, spanning fabrication, falsification, plagiarism, and breaches of the ethical or regulatory approvals a study depends on.

    What Counts as Research Misconduct in NHS-Hosted Research?

    In an NHS setting, research misconduct covers the same core categories recognised across UK research generally, but with an added patient-safety dimension. Proceeding without the ethics approval, HRA Approval, or informed consent a study requires is treated as seriously as fabricating data.

    • Fabrication or falsification of results, including patient consent records
    • Plagiarism of ideas, protocols, or published text
    • Undeclared conflicts of interest affecting clinical decision-making
    • Conducting research without the required ethical or regulatory permissions in place
    • Deviating from an approved protocol without reporting the change

    The UK Research Integrity Office (UKRIO) frames this as behaviour that “deliberately or recklessly” falls short of expected standards — a threshold that separates genuine misconduct from honest error, which most NHS trust policies classify instead as a “questionable research practice” requiring correction rather than disciplinary action.

    Who Investigates? The Sponsor, the HRA and Trust Governance

    The pivotal difference from a university-only inquiry is the statutory concept of the research sponsor. Under the UK Policy Framework for Health and Social Care Research (Health Research Authority and the four UK health departments, first published 2017), the sponsor — usually the NHS trust, a university, or a commercial entity — takes on legal responsibility for confirming a study’s initial and ongoing suitability.

    This changes who is notified and when:

    • The NHS trust’s Research and Development (R&D) office, or the trust’s Director of Research, typically leads the initial assessment of an allegation raised on trust premises
    • Serious breaches of Good Clinical Practice or the approved protocol in a clinical trial must be reported by the sponsor to the HRA (and, for medicines trials, the MHRA) within statutory timeframes — a duty that has no direct equivalent in a purely observational university study
    • The relevant NHS Research Ethics Committee must be informed where the breach affects participant safety or the ethical basis of the study
    • Where fraud is suspected, the NHS Counter Fraud Authority can be engaged in parallel to any research-integrity investigation
    • For registered doctors, nurses, or other regulated professionals, a finding of misconduct can trigger a separate referral to the General Medical Council or equivalent professional regulator, independent of the employer’s own outcome

    UKRIO’s model procedure — the template most university codes of practice are built on — is advisory rather than statutory. NHS research governance, by contrast, sits inside a framework with mandatory reporting duties attached to the sponsor role, which is why an allegation in an NHS-hosted trial can trigger regulatory notifications a university-only investigation would never generate.

    NHS Research Misconduct vs University Procedures: Where They Diverge

    Both systems share the same underlying commitments — the Concordat to Support Research Integrity (Universities UK, 2019) and UKRIO’s guidance inform both — but the accountable parties and mandatory notifications differ sharply.

    Dimension University-led research NHS-hosted clinical research
    Primary framework Concordat to Support Research Integrity (Universities UK, 2019) UK Policy Framework for Health and Social Care Research (HRA, 2017)
    Accountable party The employing institution’s “Named Person” / Responsible Officer The research sponsor, working with the host trust’s R&D office
    Investigating body Institutional panel, often with external academic peers Trust governance process, informed by sponsor obligations to the HRA
    Mandatory external notification Rare — typically only funders or journals if the record needs correcting HRA/MHRA for serious breaches; REC for participant-safety issues; Counter Fraud Authority where fraud is suspected
    Professional regulator exposure Uncommon unless a professional body membership is engaged Possible GMC, NMC or equivalent fitness-to-practise referral for regulated clinicians
    Guiding non-statutory body UKRIO model procedure UKRIO guidance, applied within HRA sponsor obligations

    The practical effect: an NHS-hosted allegation can generate two or more concurrent processes — sponsor/trust governance and, if a professional regulator becomes involved, a fitness-to-practise track — whereas a university-only case usually resolves within a single institutional procedure.

    What Dual-Employment Researchers Need to Know

    Most clinical academics hold a substantive university post alongside an honorary research contract or “letter of access” with an NHS trust, arranged through the NHS Research Passport system. This dual status means an allegation can, in principle, be picked up by either employer’s procedure — or both.

    • Establish early which organisation is the study’s sponsor: sponsor obligations under the UK Policy Framework sit with that entity, not automatically with the employer
    • Expect the university and the NHS trust to agree a lead institution for the investigation, informed by UKRIO’s guidance on cross-institutional cooperation, with the second body kept informed rather than running a parallel duplicate inquiry
    • Understand that an honorary contract does not exempt a researcher from either institution’s disciplinary powers — sanctions (suspension of research privileges, restriction of clinical duties, dismissal) can be applied independently by each party
    • Keep records of ethical approvals, protocol versions, and consent documentation accessible to both employers, since a trust R&D office and a university research office may request the same evidence separately

    Research administrators supporting joint appointments should confirm, before a study opens, which institution’s misconduct procedure will apply if a concern is raised — this sits alongside the wider governance responsibilities covered under research administration frameworks.

    Frequently Asked Questions

    What is an example of misconduct in the NHS?

    In an NHS research context, a documented example is proceeding with a clinical trial without valid ethics approval or falsifying patient consent records. Both breach the UK Policy Framework for Health and Social Care Research and trigger sponsor reporting duties to the Health Research Authority, independent of any wider workplace conduct issue.

    What are the three types of research misconduct?

    The three most widely recognised categories are fabrication (inventing data or results), falsification (manipulating data, materials, or processes to misrepresent findings), and plagiarism (using others’ work or ideas without acknowledgement). UK bodies including UKRIO also recognise a broader “questionable research practices” category for less severe lapses.

    What is considered the most serious form of research misconduct?

    Fabrication of results or consent data is generally treated as the most serious category, because it directly corrupts the evidence base and, in clinical research, can endanger patient safety. In NHS-hosted studies, fabrication findings typically prompt both sponsor notification to the HRA and professional regulator referral for the individual involved.

    What is a sackable offence in NHS?

    A confirmed finding of fabrication or falsification in NHS-hosted research is normally treated as gross misconduct and can constitute a sackable offence under trust disciplinary policy. For registered clinicians, the same finding can additionally trigger a General Medical Council fitness-to-practise referral, separate from the employer’s own decision.

    The structural distinction matters beyond individual cases. As more clinical trials run through joint university–NHS sponsorship arrangements, institutions that treat research governance as a single, unified track — rather than mapping sponsor, trust, and employer obligations separately — risk missing mandatory notifications the UK Policy Framework requires. Clear, pre-agreed lead-institution protocols for dual-employment researchers remain the most effective safeguard.